.jpeg)
Apremilast Drug Guide: Mechanism, Indications and Side Effects Explained
What is Apremilast?
Apremilast, commercially known as OTEZLA, is an oral small-molecule medication belonging to the phosphodiesterase 4 (PDE4) inhibitor class. The drug was approved by the U.S. Food and Drug Administration (FDA) in March 2014 for the treatment of various autoimmune diseases. In May 2025, the Psoriasis Group of the Chinese Medical Association Dermatology Branch released the "Expert Guidance on Apremilast Treatment of Psoriasis (2025 Edition)", further standardizing the clinical application of this medication.
Mechanism of Action
Apremilast works by inhibiting the activity of phosphodiesterase 4 (PDE4) within cells, increasing intracellular cyclic adenosine monophosphate (cAMP) levels. This process regulates the expression of tumor necrosis factor (TNF) and other inflammatory cytokines, effectively suppressing inflammatory responses. Unlike traditional biologic agents, Apremilast is administered orally, avoiding the inconvenience and pain associated with injections, reducing the medication burden for patients.
Main Indications
Apremilast is primarily used to treat the following three conditions:
Active Psoriatic Arthritis: This is a form of arthritis that primarily affects patients with psoriasis. Joint pain, stiffness and swelling are the main signs and symptoms of psoriatic arthritis.
Plaque Psoriasis: This is a chronic autoimmune disease typically characterized by red patches and white scales on the skin, affecting patients' appearance and quality of life.
Behcet's Disease: This is a rare systemic vasculitis condition that may cause oral and genital ulcers, skin lesions, and eye inflammation.
Common Side Effects
Like other medications, Apremilast may be associated with certain side effects during use. Common side effects include diarrhea, nausea, headache, upper respiratory tract infection, fatigue, vomiting, abdominal pain, and weight loss. Patients should undergo appropriate monitoring during use and consult their doctor promptly if severe discomfort occurs.
Diarrhea is a relatively common adverse reaction when using Apremilast, with an incidence rate of approximately 17.8%. Most side effects are mild to moderate and can be alleviated through dosage adjustment or symptomatic treatment.
Usage Precautions
Before taking Apremilast, patients should inform their doctor of their health status, including any history of depression, kidney function problems, or other chronic conditions. Regular follow-ups should be conducted during medication to monitor changes in physical condition. If mood changes, severe diarrhea, or other abnormal symptoms occur, medical attention should be sought promptly.
Apremilast is a prescription medication and must be used under medical supervision. Patients should not adjust the dosage or discontinue use on their own.
Conclusion
As a representative oral small-molecule medication, Apremilast provides a new treatment option for patients with psoriasis and psoriatic arthritis. Its unique mechanism of action and convenient oral administration enable more patients to benefit from targeted therapy. Patients should use it reasonably under the guidance of professional doctors to achieve optimal treatment outcomes.
[ 免责声明 ] 本页面内容来自公开渠道（如FDA官网、Drugs官网、原研药厂官网等），仅供持有医疗专业资质的人员用于医学药学研究参考，不构成任何治疗建议或药品推荐。所涉药品可能未在中国大陆获批上市，不适用于中国境内销售和使用。如需治疗，请咨询正规医疗机构。本站不提供药品销售或代购服务。
